Human neurophysins in carcinoma of the lung: relation to histology, disease stage, response rate, survival, and syndrome of inappropriate antidiuretic hormone secretion.

Maurer LH, O'Donnell JF, Kennedy S, Faulkner CS, Rist K, North WG

Cancer treatment reports1 Nov 1983Cited by 30 (Europe PMC)

PMID6315232PepBankPUB-06315232

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study12

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone12

In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Oxytocin.

01HumanNot a test of Oxytocin aloneObservational studyOther
At diagnosis, 65% of patients with small-cell lung carcinoma had elevated plasma oxytocin-associated neurophysin, vasopressin-associated neurophysin, or both.
In plain wordsIn people with small-cell lung cancer, 65% had elevated oxytocin-associated or vasopressin-associated neurophysin, or both.
Peptide
Oxytocin
Outcome
IncreaseElevated plasma oxytocin-associated or vasopressin-associated neurophysin in small-cell lung carcinoma
Study
n = 103
plasma
Outcome group
Endogenous peptide levels · Cancer
Measurements
Patients with elevated neurophysins
65%
small-cell lung carcinoma
Source sentences
Summary
At diagnosis, 65% of 103 patients with small cell carcinoma of the lung were found to have elevated plasma concentrations of vasopressin-associated human neurophysin (VP-HNP), oxytocin-associated human neurophysin (OT-HNP), or both, which were thought to be related to tumor secretion of these proteins.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-0631523201
02HumanNot a test of Oxytocin aloneObservational studyOther
At diagnosis, 24% of 103 patients with small-cell lung carcinoma were neurophysin nonsecretors.
In plain wordsIn people with small-cell lung cancer, 24% were neurophysin nonsecretors.
Peptide
Oxytocin
Outcome
Not applicableNeurophysin nonsecretor status in small-cell lung carcinoma
Study
n = 103
plasma
Outcome group
Endogenous peptide levels · Cancer
Source sentences
Summary
The remainder of patients were designated as nonsecretors (24%) or possible secretors (11%), depending upon plasma concentration of the neurophysins prior to therapy.
1 context sentence(design, population, supporting numbers)
Summary · context
At diagnosis, 65% of 103 patients with small cell carcinoma of the lung were found to have elevated plasma concentrations of vasopressin-associated human neurophysin (VP-HNP), oxytocin-associated human neurophysin (OT-HNP), or both, which were thought to be related to tumor secretion of these proteins.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-0631523210
03HumanNot a test of Oxytocin aloneObservational studyOther
At diagnosis, 11% of 103 patients with small-cell lung carcinoma were possible neurophysin secretors.
In plain wordsIn people with small-cell lung cancer, 11% were possible neurophysin secretors.
Peptide
Oxytocin
Outcome
Not applicablePossible neurophysin secretor status in small-cell lung carcinoma
Study
n = 103
plasma
Outcome group
Endogenous peptide levels · Cancer
Source sentences
Summary
The remainder of patients were designated as nonsecretors (24%) or possible secretors (11%), depending upon plasma concentration of the neurophysins prior to therapy.
1 context sentence(design, population, supporting numbers)
Summary · context
At diagnosis, 65% of 103 patients with small cell carcinoma of the lung were found to have elevated plasma concentrations of vasopressin-associated human neurophysin (VP-HNP), oxytocin-associated human neurophysin (OT-HNP), or both, which were thought to be related to tumor secretion of these proteins.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-0631523211
04HumanNot a test of Oxytocin aloneObservational studyOther
In non-small-cell lung carcinoma, 19.6% of patients had elevated plasma neurophysins.
In plain wordsIn people with non-small-cell lung cancer, 19.6% had elevated plasma neurophysins.
Peptide
Oxytocin
Outcome
IncreaseElevated plasma neurophysins in non-small-cell lung carcinoma
Study
n = 56
plasma
Outcome group
Endogenous peptide levels · Cancer
Measurements
Patients with elevated neurophysins
19.6%
non-small-cell lung carcinoma
Source sentences
Summary
In contrast, elevated plasma concentrations of the neurophysins were seen in only 19.6% of 56 patients with non-small cell carcinoma of the lung.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-0631523207
05HumanNot a test of Oxytocin aloneObservational studyOther
In non-small-cell lung carcinoma, elevated plasma neurophysins occurred at approximately equal frequencies across major cellular subtypes.
In plain wordsIn people with non-small-cell lung cancer, elevated neurophysins occurred at similar frequencies across major cellular subtypes.
Peptide
Oxytocin
Outcome
Not applicableElevated neurophysins across non-small-cell lung carcinoma cellular subtypes
Study
n = 56
plasma
Comparator
Major cellular subtypes
Outcome group
Endogenous peptide levels · Cancer
Source sentences
Summary
The levels were in general lower than those in patients with small cell carcinoma and were seen at approximately equal frequencies in each major cellular subtype.
1 context sentence(design, population, supporting numbers)
Summary · context
In contrast, elevated plasma concentrations of the neurophysins were seen in only 19.6% of 56 patients with non-small cell carcinoma of the lung.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-0631523209
06HumanNot a test of Oxytocin aloneObservational studyOther
Among patients with small-cell lung carcinoma, neurophysin secretors were more frequent in extensive (82%) than limited (40%) disease (P = 0.001).
In plain wordsIn people with small-cell lung cancer, neurophysin secretors were more common in extensive than limited disease.
Peptide
Oxytocin
Outcome
IncreaseNeurophysin secretory status by small-cell lung cancer stage
Study
n: not reported in source
plasma
Comparator
Limited disease
Outcome group
Endogenous peptide levels · Cancer
Source sentences
Summary
There was a significantly higher percentage of secretors among patients with extensive disease (82%) than among those with limited disease (40%) (P = 0.001).
1 context sentence(design, population, supporting numbers)
Summary · context
At diagnosis, 65% of 103 patients with small cell carcinoma of the lung were found to have elevated plasma concentrations of vasopressin-associated human neurophysin (VP-HNP), oxytocin-associated human neurophysin (OT-HNP), or both, which were thought to be related to tumor secretion of these proteins.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-0631523202
07HumanNot a test of Oxytocin aloneObservational studyOther
Within small-cell lung cancer stage groups, neurophysin secretory status was not correlated with response to therapy.
In plain wordsWithin small-cell lung cancer stages, neurophysin secretory status was not linked to treatment response.
Peptide
Oxytocin
Outcome
No significant changeNeurophysin secretory status and response to therapy
Study
n: not reported in source
plasma
Outcome group
Endogenous peptide levels · Cancer
Source sentences
Summary
However, within each stage group, there was no correlation between secretory status and response to therapy, survival, or histologic subtype.
1 context sentence(design, population, supporting numbers)
Summary · context
At diagnosis, 65% of 103 patients with small cell carcinoma of the lung were found to have elevated plasma concentrations of vasopressin-associated human neurophysin (VP-HNP), oxytocin-associated human neurophysin (OT-HNP), or both, which were thought to be related to tumor secretion of these proteins.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-0631523203
08HumanNot a test of Oxytocin aloneObservational studyOther
Within small-cell lung cancer stage groups, neurophysin secretory status was not correlated with survival.
In plain wordsWithin small-cell lung cancer stages, neurophysin secretory status was not linked to survival.
Peptide
Oxytocin
Outcome
No significant changeNeurophysin secretory status and survival
Study
n: not reported in source
plasma
Outcome group
Mortality · Cancer
Source sentences
Summary
However, within each stage group, there was no correlation between secretory status and response to therapy, survival, or histologic subtype.
1 context sentence(design, population, supporting numbers)
Summary · context
At diagnosis, 65% of 103 patients with small cell carcinoma of the lung were found to have elevated plasma concentrations of vasopressin-associated human neurophysin (VP-HNP), oxytocin-associated human neurophysin (OT-HNP), or both, which were thought to be related to tumor secretion of these proteins.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-0631523204
09HumanNot a test of Oxytocin aloneObservational studyOther
Within small-cell lung cancer stage groups, neurophysin secretory status was not correlated with histologic subtype.
In plain wordsWithin small-cell lung cancer stages, neurophysin secretory status was not linked to histologic subtype.
Peptide
Oxytocin
Outcome
No significant changeNeurophysin secretory status and histologic subtype
Study
n: not reported in source
plasma
Outcome group
Endogenous peptide levels · Cancer
Source sentences
Summary
However, within each stage group, there was no correlation between secretory status and response to therapy, survival, or histologic subtype.
1 context sentence(design, population, supporting numbers)
Summary · context
At diagnosis, 65% of 103 patients with small cell carcinoma of the lung were found to have elevated plasma concentrations of vasopressin-associated human neurophysin (VP-HNP), oxytocin-associated human neurophysin (OT-HNP), or both, which were thought to be related to tumor secretion of these proteins.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-0631523205
10HumanNot a test of Oxytocin aloneObservational studyOther
Patients initially classified as neurophysin nonsecretors maintained nonsecretor status through remission and relapse.
In plain wordsPeople initially classified as neurophysin nonsecretors kept that status through remission and relapse.
Peptide
Oxytocin
Outcome
Not applicableNeurophysin nonsecretor status through remission and relapse
Study
n: not reported in source
plasma
Outcome group
Endogenous peptide levels · Cancer
Source sentences
Summary
In addition, patients who initially were nonsecretors or possible secretors maintained this status throughout the course of disease remission and subsequent relapse.
1 context sentence(design, population, supporting numbers)
Summary · context
At diagnosis, 65% of 103 patients with small cell carcinoma of the lung were found to have elevated plasma concentrations of vasopressin-associated human neurophysin (VP-HNP), oxytocin-associated human neurophysin (OT-HNP), or both, which were thought to be related to tumor secretion of these proteins.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-0631523206
11HumanNot a test of Oxytocin aloneObservational studyOther
Plasma neurophysin levels in non-small-cell lung carcinoma were generally lower than in small-cell lung carcinoma.
In plain wordsIn people with non-small-cell lung cancer, plasma neurophysin levels were lower than in small-cell lung cancer.
Peptide
Oxytocin
Outcome
DecreasePlasma neurophysin level in non-small-cell versus small-cell lung carcinoma
Study
n: not reported in source
plasma
Comparator
Small-cell carcinoma
Outcome group
Endogenous peptide levels · Cancer
Source sentences
Summary
The levels were in general lower than those in patients with small cell carcinoma and were seen at approximately equal frequencies in each major cellular subtype.
1 context sentence(design, population, supporting numbers)
Summary · context
In contrast, elevated plasma concentrations of the neurophysins were seen in only 19.6% of 56 patients with non-small cell carcinoma of the lung.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-0631523208
12HumanNot a test of Oxytocin aloneObservational studyOther
Patients initially classified as possible neurophysin secretors maintained possible-secretor status through remission and relapse.
In plain wordsPeople initially classified as possible neurophysin secretors kept that status through remission and relapse.
Peptide
Oxytocin
Outcome
Not applicablePossible neurophysin secretor status through remission and relapse
Study
n: not reported in source
plasma
Outcome group
Endogenous peptide levels · Cancer
Source sentences
Summary
In addition, patients who initially were nonsecretors or possible secretors maintained this status throughout the course of disease remission and subsequent relapse.
1 context sentence(design, population, supporting numbers)
Summary · context
At diagnosis, 65% of 103 patients with small cell carcinoma of the lung were found to have elevated plasma concentrations of vasopressin-associated human neurophysin (VP-HNP), oxytocin-associated human neurophysin (OT-HNP), or both, which were thought to be related to tumor secretion of these proteins.
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-0631523212

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 20:03 UTC
Study results updated
Version 1
9 Oct 2026, 02:54 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.